ViewRay (VRAY) Tops Q4 EPS by 6c, Revenues Beat; Offers FY19 Revenues Below Consensus

ViewRay (NASDAQ: VRAY) reported Q4 EPS of ($0.17), $0.06 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $20.7 million versus the consensus estimate of $20.38 million.

• Total revenue of $20.7 million, primarily from 3 revenue units and 1 system upgrade in the fourth quarter of 2018, compared to fourth quarter 2017 revenue of $19.9 million, primarily from 4 revenue units.
• Received 8 new orders for MRIdian systems totaling $48.7 million in the fourth quarter of 2018, compared to 6 new orders totaling $34.1 million in the fourth quarter of 2017.

"We are focused on becoming the standard of care in radiation oncology," said Scott Drake, President and CEO. "We have made significant progress on our commercial, innovation and clinical pipelines. In 2019, we are well positioned to drive further growth, therapy adoption and extend our innovation lead."

GUIDANCE:

ViewRay sees FY2019 revenue of $111-124 million, versus the consensus of $124.33 million.

For earnings history and earnings-related data on ViewRay (VRAY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery